Company Description
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer.
The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.
The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer.
eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Craig R. Jalbert CIRA |
Contact Details
Address: 142 North Cedros Avenue, Suite B Solana Beach, California 92075 United States | |
| Phone | (858) 925-8215 |
| Website | effector.com |
Stock Details
| Ticker Symbol | EFTR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001828522 |
| CUSIP Number | 28202V108 |
| ISIN Number | US28202V2079 |
| Employer ID | 85-3306396 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Stephen T. Worland Ph.D. | Chief Executive Officer, President and Director |
| Michael Byrnes M.B.A. | Chief Financial Officer |
| Dr. Douglas Warner M.D. | Chief Medical Officer |
| Dr. Davide Ruggero Ph.D. | Co-Founder and Member of Clinical and Scientific Advisory Board |
| Dr. Kevan M. Shokat Ph.D. | Co-Founder and Member of Clinical and Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 26, 2024 | 8-K | Current Report |
| Jun 25, 2024 | 8-K | Current Report |
| Jun 24, 2024 | 8-K | Current Report |
| Jun 14, 2024 | 8-K | Current Report |
| May 20, 2024 | 8-K | Current Report |
| May 17, 2024 | 424B3 | Prospectus |
| May 17, 2024 | 8-K | Current Report |
| May 13, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 9, 2024 | 424B5 | Filing |
| May 9, 2024 | 424B3 | Prospectus |